Could Sanders' universal healthcare dreams come true in one state?

Caitlin Wilson | | Health Exec | Policy & Regulations

Vermont Sen. Bernie Sanders’ schedule has just opened up, now that he’s no longer campaigning to be the Democratic nominee for president. Some Colorado activists say they know the perfect way he can spend his extra time.

Political organizers there want Sanders to help pass ColoradoCare, a proposed universal health care policy for the state, which is up for a vote in November.

National state-sponsored universal healthcare was a major part of Sanders’ policy platform. Proponents in Colorado said his star power used to campaign for the measure could mean victory for the policy in the fall.

Check out Kaiser Health News’ report on ColoradoCare’s chances of passing. 

Campaign For Universal Health Care In Colorado Seeks Bernie Sanders' Help List…

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.